Harbour BioMed and Kelun-Biotech's Breakthrough in Atopic Dermatitis Treatment with IND Approval Harbour BioMed and Kelun-Biotech have received NMPA approval for their innovative treatment, HBM7575/SKB575, targeting atopic dermatitis effectively.

Harbour BioMed and Kelun-Biotech's Breakthrough in Atopic Dermatitis Treatment with IND Approval #China #Kelun-Biotech #Rotterdam #Harbour_BioMed #HBM7575